​

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MDGL Stock Forecast

Madrigal Pharmaceuticals (MDGL) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $710.22, with a high of $964.00 and a low of $542.00. This represents a 49.75% increase from the last price of $474.28.

$200 $360 $520 $680 $840 $1 High: $964 Avg: $710.22 Low: $542 Last Closed Price: $474.28

MDGL Stock Rating

Madrigal Pharmaceuticals stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (86.96%), 2 Hold (8.70%), 1 Sell (4.35%), and 0 Strong Sell (0.00%).

Buy
Total 23 1 2 20 0 Strong Sell Sell Hold Buy Strong Buy

MDGL Price Target Upside V Benchmarks

TypeNameUpside
StockMadrigal Pharmaceuticals49.75%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2416
Avg Price Target$625.50$619.50$658.69
Last Closing Price$474.28$474.28$474.28
Upside/Downside31.88%30.62%38.88%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 261102--13
May, 263112--16
Apr, 263112--16
Mar, 263112--16
Feb, 263122--17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 11, 2026Morgan Stanley$542.00$471.3215.00%14.28%
May 13, 2026Truist Financial$709.00$513.3038.13%49.49%
May 07, 2026Evercore ISI$649.00$539.7320.25%36.84%
May 07, 2026Canaccord Genuity$578.00$539.737.09%21.87%
Jan 27, 2026Barclays$964.00$500.3992.65%103.26%
Jan 14, 2026Andrea TanGoldman Sachs$571.00$493.9015.61%20.39%
Jan 06, 2026Andy ChenWolfe Research$579.00$588.40-1.60%22.08%
Dec 19, 2025Yasmeen RahimiPiper Sandler$900.00$588.8152.85%89.76%
Dec 19, 2025UBS$900.00$544.4165.32%89.76%
Nov 21, 2025H.C. Wainwright$620.00$558.6110.99%30.72%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 11, 2026Bank of America SecuritiesNeutralNeutralhold
Jun 01, 2026Wells FargoOverweightupgrade
Jan 27, 2026BarclaysOverweightinitialise
Jan 20, 2026CitigroupOutperformOutperformhold
Jan 14, 2026Goldman SachsBuyBuyhold
Jan 12, 2026Cowen & Co.BuyBuyhold
Jan 06, 2026Wolfe ResearchOutperformPeer Performdowngrade
Dec 19, 2025Piper SandlerOverweightOverweighthold
Dec 11, 2025B. RileyBuyBuyhold
Nov 21, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-50 $-20 $10 $40 $70 $100 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-19.99$-21.90$-12.85---
Avg Forecast$-19.44$-23.62$-12.97$2.87$32.05$57.26
High Forecast$-18.30$-22.60$-3.19$9.94$46.90$75.38
Low Forecast$-20.11$-24.76$-22.28$-4.22$7.13$34.14
Surprise %2.83%-7.28%-0.93%---

Revenue Forecast

$0 $800M $2B $2B $3B $4B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$180.13M$958.40M---
Avg Forecast-$172.04M$514.95M$1.02B$1.88B$2.92B
High Forecast-$182.74M$633.56M$1.02B$1.94B$3.64B
Low Forecast-$161.27M$412.06M$1.02B$1.82B$2.02B
Surprise %-4.71%86.12%---

Net Income Forecast

$-500M $-100M $300M $700M $1B $2B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-373.63M$-465.89M$-288.28M---
Avg Forecast$-373.63M$-442.50M$-297.44M$117.58M$782.67M$1.07B
High Forecast$-342.06M$-422.26M$-59.61M$185.69M$876.45M$1.41B
Low Forecast$-375.85M$-462.74M$-416.30M$-78.80M$133.33M$637.91M
Surprise %-5.29%-3.08%---

MDGL Forecast FAQ

Is Madrigal Pharmaceuticals stock a buy?

Madrigal Pharmaceuticals stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Madrigal Pharmaceuticals is a favorable investment for most analysts.

What is Madrigal Pharmaceuticals's price target?

Madrigal Pharmaceuticals's price target, set by 23 Wall Street analysts, averages $710.22 over the next 12 months. The price target range spans from $542 at the low end to $964 at the high end, suggesting a potential 49.75% change from the previous closing price of $474.28.

How does Madrigal Pharmaceuticals stock forecast compare to its benchmarks?

Madrigal Pharmaceuticals's stock forecast shows a 49.75% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Madrigal Pharmaceuticals over the past three months?

  • June 2026: 7.69% Strong Buy, 76.92% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 18.75% Strong Buy, 68.75% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 18.75% Strong Buy, 68.75% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Madrigal Pharmaceuticals’s EPS forecast?

Madrigal Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $2.87, marking a -122.33% decrease from the reported $-12.85 in 2025. Estimates for the following years are $32.05 in 2027, and $57.26 in 2028.

What is Madrigal Pharmaceuticals’s revenue forecast?

Madrigal Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $1.02B, reflecting a 6.43% increase from the reported $958.4M in 2025. The forecast for 2027 is $1.88B, and $2.92B for 2028.

What is Madrigal Pharmaceuticals’s net income forecast?

Madrigal Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $117.58M, representing a -140.79% decrease from the reported $-288M in 2025. Projections indicate $782.67M in 2027, and $1.07B in 2028.